Back to search

Japan· JP-4291082F2024

カピバセルチブ

A capivasertib product containing カピバセルチブ, registered in Japan by アストラゼネカ, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

On Japan’s NHI price listATC L01EX27

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedカピバセルチブATCL01EX27REGISTER NO.JP-4291082F2024PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Capivasertib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EX27 (capivasertib), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 8 of them publish a price we can compare per daily dose

Capivasertib · ATC L01EX27

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of capivasertib costs, country by country.

Normalised to the WHO defined daily dose (0.46 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Capivasertib · price per daily dose (0.46 g)

USD · FX 28 Sept 2026

  • CH Switzerland$320.95
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
カピバセルチブ
Manufacturer
アストラゼネカ
Country
Japan (JP)
ATC code
L01EX27
ATC class
Capivasertib
Defined daily dose
0.46 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e955d43d-bf42-47e3-8b4f-827c314499e9
GET /v1/drugs/e955d43d-bf42-47e3-8b4f-827c314499e9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "200mg1錠",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "4291082F2024",
  "category": "内用薬",
  "price_yen": 3430,
  "generic_name": "カピバセルチブ",
  "product_name_jp": null,
  "therapeutic_class": "4291",
  "transitional_expiry": "3430"
}

See everything about capivasertib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.